BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33092125)

  • 1. Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics-A Review.
    Stankovic JSK; Selakovic D; Mihailovic V; Rosic G
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence.
    Alberti P
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):487-497. PubMed ID: 31116618
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity.
    Carozzi VA; Marmiroli P; Cavaletti G
    Curr Cancer Drug Targets; 2010 Nov; 10(7):670-82. PubMed ID: 20578989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Evidence of Interaction between Nutraceutical Supplementation and Platinum-based Chemotherapy.
    Cocetta V; Tinazzi M; Giacomini I; Rosato B; Ragazzi E; Berretta M; Montopoli M
    Curr Med Chem; 2023; 30(19):2141-2164. PubMed ID: 35638272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
    Hill A; Bergin P; Hanning F; Thompson P; Findlay M; Damianovich D; McKeage MJ
    BMC Cancer; 2010 Aug; 10():451. PubMed ID: 20731872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection.
    McQuade RM; Stojanovska V; Bornstein JC; Nurgali K
    Pharmacol Res; 2018 Nov; 137():104-113. PubMed ID: 30278221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches.
    Screnci D; McKeage MJ
    J Inorg Biochem; 1999 Oct; 77(1-2):105-10. PubMed ID: 10626361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
    Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
    Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicities of the platinum antineoplastic agents.
    Markman M
    Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
    Bondad N; Boostani R; Barri A; Elyasi S; Allahyari A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1575-1582. PubMed ID: 32063109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based chemotherapy induces demyelination of Schwann cells in oral squamous cell carcinoma treatment.
    Wang X; Yang W; Wang L; Zheng L; Choi WS
    Toxicol Appl Pharmacol; 2023 Dec; 481():116751. PubMed ID: 37944569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
    Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
    Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    de Castria TB; da Silva EM; Gois AF; Riera R
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects.
    Conklin KA
    Nutr Cancer; 2000; 37(1):1-18. PubMed ID: 10965514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth.
    Das B; Antoon R; Tsuchida R; Lotfi S; Morozova O; Farhat W; Malkin D; Koren G; Yeger H; Baruchel S
    Neoplasia; 2008 Oct; 10(10):1105-19. PubMed ID: 18813359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum compounds in children with cancer: toxicity and clinical management.
    Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
    Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.